Amgen’s AMG 811 Fails to Improve Lupus Outcomes in Phase 1 Trial

Patients with systemic lupus erythematosus (SLE) with or without lupus nephritis (LN) showed no clinical benefit when treated with Amgen‘s investigative anti-interferon-gamma antibody, AMG 811, in a Phase 1b  (NCT00818948) clinical trial. Some indicators of the disease dropped in response to the treatment, but less so in…